Literature DB >> 3129191

Comparative study of the antitumor effect of two types of murine recombinant interferons, (beta) and (gamma), against B16-F10 melanoma.

M Sakurai1, M Iigo, T Tamura, A Otsu, Y Sasaki, H Nakano, K Nakagawa, K Minato, Y Ohe, N Saijo.   

Abstract

A comparative study of the antitumor effect of murine recombinant interferon(beta) less than Mu-rIFN(beta) greater than and murine recombinant interferon(gamma) less than Mu-rIFN(gamma) greater on B16-F10 melanoma was conducted. Administration of Mu-rIFN(gamma) i.p. into C57BL/6 mice on days 1 to 7 produced a higher suppressive effect than Mu-rIFN(beta) both on the growth of s.c. implanted tumor and on the formation of artificial pulmonary metastasis. Pharmacokinetic study of Mu-rIFN(gamma) demonstrated that high plasma levels were retained for a long time. In clonogenic assay, Mu-rIFN(gamma) at 1000 units/ml showed about 80% inhibition of colonies of B16-F10 melanoma. However, Mu-rIFN(beta) hardly inhibited the colonies, even at 1000 units/ml. Augmentation of natural killer (NK) cytotoxicity was much greater with Mu-rIFN(beta) than Mu-rIFN(gamma), whereas Mu-rIFN(gamma) enhanced the cytotoxicity of peritoneal macrophages more strongly than Mu-rIFN(beta). Injection of Mu-rIFN(gamma) i.p. 1 day before tumor challenge also inhibited the formation of pulmonary metastasis of B16-F10 melanoma. However, pretreatment of mice with carrageenan significantly suppressed the inhibitory effect of Mu-rIFN(gamma). From these results, it is suggested that the inhibitory effect of Mu-rIFN(gamma) on the tumor growth and metastases of B16-F10 melanoma is mediated partly by direct antitumor effect and partly by the activation of macrophages, and that the augmentation of NK activity contributes mainly to the antitumor effect of Mu-rIFN(beta).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129191     DOI: 10.1007/bf00205602

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  22 in total

1.  Inhibitory effect of murine recombinant interferon (beta) on the pulmonary metastasis of B-16 melanoma.

Authors:  M Sakurai; M Iigo; A Ozaki; J R Jett; Y Sasaki; A Hoshi; N Saijo
Journal:  Jpn J Cancer Res       Date:  1986-08

2.  Selection of successive tumour lines for metastasis.

Authors:  I J Fidler
Journal:  Nat New Biol       Date:  1973-04-04

Review 3.  Immunomodulation by interferons: recent developments.

Authors:  J De Maeyer-Guignard; E De Maeyer
Journal:  Interferon       Date:  1985

4.  Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. II. Role of host mechanisms.

Authors:  F Belardelli; I Gresser; C Maury; M T Maunoury
Journal:  Int J Cancer       Date:  1982-12-15       Impact factor: 7.396

5.  Purified human immune interferon has more potent anticellular activity than fibroblast or leukocyte interferon.

Authors:  J E Blalock; J A Georgiades; M P Langford; H M Johnson
Journal:  Cell Immunol       Date:  1980-02       Impact factor: 4.868

6.  Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators.

Authors:  I J Fidler; Z Barnes; W E Fogler; R Kirsh; P Bugelski; G Poste
Journal:  Cancer Res       Date:  1982-02       Impact factor: 12.701

7.  Inhibitory effect of interferon on the growth of spontaneous mammary tumors in mice.

Authors:  E De Clercq; Z X Zhang; K Huygen; R Leyten
Journal:  J Natl Cancer Inst       Date:  1982-09       Impact factor: 13.506

8.  Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. I.

Authors:  F Belardelli; I Gresser; C Maury; M T Maunoury
Journal:  Int J Cancer       Date:  1982-12-15       Impact factor: 7.396

9.  Importance of treatment regimen of interferon as an antitumor agent.

Authors:  S H Lee; H Chiu; E Rinderknecht; W Sabo; N Stebbing
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

10.  Relative contribution of antiproliferative and host immunity-associated activity of mouse interferon in murine tumor therapy.

Authors:  T Kataoka; F Oh-hashi; Y Sakurai; K Usuki; N Ida
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

View more
  2 in total

1.  Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses.

Authors:  M J Litton; M Dohlsten; J Hansson; A Rosendahl; L Ohlsson; T Kalland; J Andersson; U Andersson
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

Review 2.  The potential of interferons in malignant disease.

Authors:  K Okita; T Kaneko
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.